Clinical Trials /

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

NCT01934894

Description:

This phase II trial will combine two agents, cabazitaxel and lapatinib, to treat patients with metastatic breast cancer (MBC) which has metastasized to the brain. The first portion of the study will determine the optimal dose of the cabazitaxel/lapatinib combination to administer to patients. After determining the optimal dose, patients will continue treatment with cabazitaxel and lapatinib to assess response to treatment with these agents.

Related Conditions:
  • Brain metastasis
  • Breast Carcinoma
Recruiting Status:

Terminated

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
  • Official Title: Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Clinical Trial IDs

  • ORG STUDY ID: SCRI BRE 200
  • NCT ID: NCT01934894

Conditions

  • Metastatic Breast Cancer With Intracranial Metastases

Interventions

DrugSynonymsArms
cabazitaxelJevtana, XRP6258cabazitaxel and lapatinib combination
lapatinibTykerb, GW572016cabazitaxel and lapatinib combination

Purpose

This phase II trial will combine two agents, cabazitaxel and lapatinib, to treat patients with metastatic breast cancer (MBC) which has metastasized to the brain. The first portion of the study will determine the optimal dose of the cabazitaxel/lapatinib combination to administer to patients. After determining the optimal dose, patients will continue treatment with cabazitaxel and lapatinib to assess response to treatment with these agents.

Detailed Description

      This is an open-label, non-randomized, Phase II study with a lead-in safety cohort. Through
      the safety lead-in portion of this trial we will define the optimal dose of cabazitaxel when
      given in combination with lapatinib for patients with HER2-positive MBC and CNS metastases.
      The Phase II portion will further assess intracranial response rate in patients with
      HER2-positive MBC and CNS metastases. Toxicity and progression free survival (PFS) will be
      obtained and evaluated. The trial will be conducted at multiple study sites by SCRI
      Development Innovations.
    

Trial Arms

NameTypeDescriptionInterventions
cabazitaxel and lapatinib combinationExperimentalCabazitaxel 1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined) Lapatinib PO once daily (dose to be determined) Treatment cycles will be repeated every 3 weeks.
  • cabazitaxel
  • lapatinib

Eligibility Criteria

        Inclusion Criteria:

          1. Patients with HER2-positive MBC and unequivocal evidence of brain metastases.

          2. Documented HER2-positive tumor status at study entry defined as:

               -  Immunohistochemical (IHC) score 3+ or

               -  IHC score 1-2+ and confirmed as FISH (Fluorescence in situ hybridization)
                  positive (based on ASCO-CAP guidelines 2013) or

               -  FISH or ISH (in situ hybridization) positive (based on ASCO-CAP guidelines 2013)

          3. Patient must have at least one measurable brain lesion (defined as any lesion ≥ 5mm cm
             in the longest dimension), on T1 weighted, gadolinium enhanced MRI. Patients may have
             had surgical excisions of brain metastases provided at least one lesions meets the
             following criteria:

               -  Patients with brain metastases previously untreated with any intra-cranial
                  radiation (i.e. no whole brain radiation therapy [WBRT]/partial brain radiation
                  or stereotactic radiosurgery [SRS]) must have at least one intra-cranial tumor
                  lesion that is ≥ 5mm.

               -  Patients with brain metastases previously untreated with any intracranial
                  radiation (i.e., no whole brain radiation therapy [WBRT]/partial brain radiation
                  or stereotactic radiosurgery [SRS]) must have at least one intracranial tumor
                  lesion that is ≥ 5mm.

               -  Patients with brain metastases previously treated with WBRT/partial brain
                  radiation only must have at least one intracranial tumor lesion ≥ 5mm and must
                  have evidence of intracranial progressive disease

               -  Patients previously treated with WBRT/partial brain radiation and SRS must have
                  at least one intracranial tumor lesion ≥ 5mm that was not treated with SRS and
                  must have intracranial disease.

               -  Patients previously treated with SRS must either demonstrate disease progression
                  ≥ 12 weeks after completing SRS with a lesion measuring ≥ 5mm or must have at
                  least one intracranial tumor lesion ≥ 5mm that was not treated with SRS.

          4. Patients who have received WBRT/partial brain radiation for intra-cranial metastases
             are eligible if treatment was completed ≥28 days prior to the first dose of study
             drug.

          5. Estrogen receptor (ER) and progesterone receptor (PR) status in the primary or most
             recent tumor assessment must be known or pending at the time of study registration.
             Patient's ER/PR status (i.e., positive or negative) does not influence enrollment but
             is a requirement.

          6. Patient must have received prior treatment with HER2-directed therapy such as
             trastuzumab, either in the adjuvant or metastatic setting.

          7. Prior treatment with lapatinib in the (neo)adjuvant and metastatic setting.

          8. Patients without prior chemotherapy for MBC are eligible provided the patients
             relapsed during adjuvant therapy with trastuzumab or ≤6 months following completion of
             adjuvant therapy. Otherwise, there is no specific minimum or maximum number of
             previous chemotherapy regimens for MBC.

          9. Patients must have completed cytotoxic chemotherapy ≥21 days (for an every 3-week
             regimen) or ≥14 days (for an every 2-week or weekly regimen) and have recovered from
             or come to a new chronic or stable baseline from all treatment-related toxicities in
             order to be eligible for study treatment.

               -  Patient must have completed biologic therapy ≥3 weeks or 5-half lives whichever
                  is shorter.

               -  Patient must be discontinued from hormonal therapy a minimum of 1 day prior to
                  the first dose of study treatment.

               -  Patients receiving palliative radiation to bone, soft tissue or any other disease
                  sites must have completed this ≥1 week prior to the first dose of study
                  treatment.

         10. Patients must have recovered (>2 week recovery is mandated) from any acute
             neurosurgical intervention for metastatic CNS disease (e.g., resection, shunt
             placement) and must be clinically stable. These patients must have residual measurable
             CNS lesion(s) following the surgical procedure if this site is to serve as the target
             lesion.

         11. Patients must be neurologically stable, and if receiving steroids, must be on stable
             or decreasing doses of corticosteroids and/or anticonvulsants for defined as being on
             stable low doses of corticosteroids ≥ 5 days prior to the first dose of study
             treatment.

         12. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2.

         13. Adequate hematologic, renal, and hepatic function.

         14. Adequate coagulation parameters.

         15. Other laboratory testing:

               -  Serum magnesium ≥ the institutional lower limit of normal (LLN)

               -  Serum potassium ≥ the institutional LLN

         16. Left-ventricular-ejection fraction (LVEF) of ≥50% by an echocardiogram (ECHO) or by a
             multiple-gated acquisition (MUGA)

         17. Male patients willing to use adequate contraceptive measures.

         18. Female patients who are not of child-bearing potential, and female patients of
             child-bearing potential who agree to use adequate contraceptive measures, who are not
             breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours
             prior to start of treatment.

         19. Life expectancy ≥12 weeks.

         20. Ability to swallow oral medications.

         21. Willingness and ability to comply with trial and follow-up procedures.

         22. Ability to understand the nature of this trial and give written informed consent.

        Exclusion Criteria:

          1. Previous treatment with cabazitaxel.

          2. CNS disease requiring immediate neurosurgical intervention (e.g., resection, shunt
             placement, etc.).

          3. Leptomeningeal metastases as the only site of CNS metastases. Patients with
             parenchymal brain metastases and leptomeningeal metastases are eligible provided they
             meet all other eligibility criteria.

          4. Peripheral neuropathy ≥Grade 2 (CTCAE v4.0).

          5. Concurrent treatment with radiation therapy, hormonal therapy, biologic therapy or
             chemotherapy is not allowed. Low dose corticosteroids (≤30 mg/day prednisone or its
             equivalent) are allowed.

          6. Concurrent treatment with drugs known to be moderate and strong inhibitors or inducers
             of isoenzyme CYP3A that cannot be discontinued or switched to different medication
             prior to starting study drug.

          7. Concurrent use of St. John's wort and grapefruit/grapefruit juice ≤7 days prior to
             starting study drug is not allowed.

          8. Presence of active gastrointestinal (GI) disease or other condition that in the
             opinion of the investigator will interfere significantly with the absorption,
             distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease,
             uncontrolled nausea, or vomiting).

          9. Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis
             C (HCV).

         10. Presence of other active cancers, or history of treatment for invasive cancer ≥3
             years. Patients with stage I cancer who have received definitive local treatment with
             curative intent at least 3 years previously, and are considered unlikely to recur are
             eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive)
             are eligible, as are patients with history of non-melanoma skin cancer.

         11. Any severe and/or uncontrolled medical conditions or other conditions that could
             affect participation in the study such as:

               -  Symptomatic congestive heart failure (CHF) of New York Heart Association Class
                  III or IV.

               -  QTc > 480 ms on screening ECG (using the Fredericia formula)

               -  Poorly controlled or clinically significant atherosclerotic vascular disease
                  including cerebrovascular accident (CVA), transient ischemic attack (TIA),
                  angioplasty, cardiac or vascular stenting in the past 6 months

               -  Active (acute or chronic) or uncontrolled severe infections.

               -  Active hepatic or biliary disease (except for patients with Gilbert's syndrome,
                  asymptomatic gallstones, liver metastases, or stable chronic liver disease per
                  investigator assessment).

         12. Known hypersensitivity to cabazitaxel or other drugs formulated with polysorbate 80.

         13. Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.

         14. Inability or unwillingness to comply with study and/or follow-up procedures outlined
             in the protocol.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:CNS Objective Response
Time Frame:every 6 weeks thru cycle 8, then every 9 weeks until treatment discontinuation, projected 1 year
Safety Issue:
Description:The number of patients with Complete and Partial Response (CR+PR) of CNS lesions assessed per modified RECIST Criteria for Evaluation of Intracranial Disease. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion.

Secondary Outcome Measures

Measure:CNS Clinical Benefit Response
Time Frame:every 6 weeks thru cycle 8, and every 3 cycles thereafter until treatment discontinuation, projected 1 year
Safety Issue:
Description:The number of patients with Complete Response, Partial Response or Stable Disease extending beyond 6 months (CR+PR+SD ≥ 6 months), determined by RECIST v1.1. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion; SD=Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since the treatment started.
Measure:Extra-Cranial Objective Response
Time Frame:every 6 weeks for 8 cycles, then every 9 weeks until treatment discontinuation, up to 1 year
Safety Issue:
Description:The number of participants having Complete and Partial Responses (CR+PR) of extra-cranial lesions assessed per RECIST v1.1 Criteria. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion.
Measure:CNS Progression Free Survival
Time Frame:every 6 weeks thru cycle 8, then every 9 weeks until treatment discontinuation, projected 1 year
Safety Issue:
Description:Evaluate the three and six-month CNS progression free survival measured from date of first protocol treatment until tumor progression or death.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Terminated
Lead Sponsor:SCRI Development Innovations, LLC

Trial Keywords

  • HER2-positive breast cancer
  • intracranial metastases
  • lapatinib
  • cabazitaxel

Last Updated

June 1, 2017